Rhoen Klinikum (RHK) H2 2024 earnings summary

Executive summary

• Achieved forecasted results for 2024, with revenue and earnings rising for the third consecutive year despite sector headwinds.

• Treated 912,965 patients, a 3.5% increase year-over-year, and maintained robust operational performance.

• Outperformed sector peers, with most German hospitals expecting losses, while RHÖN-KLINIKUM and its university hospital UKGM posted profits.

• Continued strategic investments in digitalization, sustainability, and modern care delivery, leveraging affiliation with Asklepios Group.

• Board and Supervisory Board confirmed strong governance, compliance, and risk management practices.

Financial highlights

• Revenue increased by 9.0% to €1,595.6 million compared to the previous year.

• EBITDA rose 4.6% to €110.8 million; EBIT up 19.1% to €48.1 million; consolidated profit up 12.4% to €45.2 million year-over-year.

• Earnings per share reached €0.65, up from €0.58 in 2023.

• Equity ratio remained high at 71.4%; net liquidity increased to €259.9 million.

• Cash flow from operating activities was €127.6 million; investments totaled €73.5 million.

Outlook and guidance

• For 2025, expects revenue of €1.7 billion (+/- 5%) and EBITDA between €110 million and €125 million.

• Anticipates moderate increases in patient cases and cost weights.

• Outlook reflects ongoing regulatory changes and sector uncertainties.